Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia

• Status: Completed
• Trial end date: 2005-12-01
• Target enrollment: 0
• Participant gender: All

Summary

It is hypothesized that the atypical antipsychotic, Seroquel, will cause significant reduction in drug and alcohol cravings in patients with schizophrenia and comorbid cocaine and/methamphetamine dependence compared to the atypical antipsychotic, risperidone (Risperdal).

Patients treated with Seroquel will have less use of cocaine and/or methamphetamine as measured by the Time Line Follow-back, over a 24-week follow-up period.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Creighton University
• Collaborator: AstraZeneca
• Treatments: Amphetamine; Cocaine; Quetiapine Fumarate; Risperidone

Criteria

Inclusion Criteria:

1. Ages 19 - 65.

2. Diagnosis of schizophrenia or schizoaffective disorder with comorbid cocaine and/or amphetamine abuse/dependence as confirmed by Structured Clinical Interview for DSM-IV.

3. Comorbid diagnoses of depression, anxiety and/or personality disorders are permitted.

4. Ability to provide signed informed consent.

5. Stable general medical health.

Exclusion Criteria:

1. Dangerous to self or others.

2. Pregnancy, inability or unwillingness to use approved methods of birth control.

3. Inability or unwillingness to provide signed informed consent.

4. Diagnosis of bipolar disorder, primary major depressive disorder (As major Axis I diagnosis).

5. Inability to attend outpatient research clinic.

6. Medical conditions, which would preclude use of Seroquel.

7. Absolute need for ongoing treatment with antipsychotic other than Seroquel.

8. Medical instability defined as likelihood of needing to change prescription medication during the course of the study.

9. Patients currently taking quetiapine or risperidone.

10. Patients with unsuccessful treatment with quetiapine or risperidone.

11. Subjects with a HAM-D score of ≥20 at screening.